Wednesday, February 8, 2017
Amgen Gets FDA Approval On Kidney Disease Treatment
Thousand Oaks-based Amgen said late Tuesday that it has received U.S. Food and Drug Administration (FDA) approval on a treatment for kidney disease. Amgen said the FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. According to the company, its new treatment is the first approved for the condition in 12 years.